Lexicon Pharmaceuticals and Lexeo Therapeutics each raise $250M and $95M in oversubscribed private placements.

Lexicon Pharmaceuticals and Lexeo Therapeutics each announced oversubscribed private placements totaling $250M and $95M, respectively. Lexicon plans to issue Series A Convertible Preferred Stock to accredited investors, while Lexeo Therapeutics will sell common stock to institutional and healthcare investors. Both private placements aim to extend their respective companies' runways and support their ongoing clinical programs.

March 11, 2024
5 Articles